Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors

Radiology and Oncology

Gilberto Lopes¹  Matjaz Zwitter²  Antonio Rossi³  Massimo Di Maio⁴  Maja Pohar Perme⁵ 

[1] Centro Paulista de Oncologia e HCor Onco, members of the Oncoclinicas do Brasil Group, Sao Paulo, Brazil and Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USAOther articles by this author:;Corresponding authorInstitute of Oncology Ljubljana, Ljubljana, SloveniaFaculty of Medicine, University of Maribor, Maribor, Slovenia;Division of Medical Oncology, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo (FG), ItalyOther articles by this author:;Division of Medical Oncology, Mauriziano Hospital, Oncology Department, University of Turin, Torino, ItalyOther articles by this author:;Institute for Biostatistics and Medical Informatics, Faculty of Medicine, University of Ljubljana, Ljubljana, SloveniaOther articles by this author:

关键词: NSCLC;    intercalated treatment;    EGFR;    tyrosine-kinase inhibitors;   

DOI  :  10.1515/raon-2017-0029

学科分类：肿瘤学

来源: Onkoloski Institut Ljubljana / Institute of Oncology Ljubljana

【 摘 要 】

BackgroundWhen treating patients with advanced non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors and chemotherapy, intercalated schedule with time separation between the two classes of drugs should avoid their mutual antagonism. In a survey of published trials, we focus on relation between eligibility criteria and effectiveness of intercalated treatment.

【 授权许可】

Unknown